Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma

To join this study, you would generally need to be at least 18 years old and have a confirmed diagnosis of advanced stomach or oesophago-gastric adenocarcinoma that has spread to other parts of your body. You should have already received and tried two or three previous types of treatment for your advanced cancer and your cancer should have grown despite these treatments. This includes common chemotherapy drugs like platinum salts, fluoropyrimidine, and irinotecan or taxane, and potentially other treatments like anti-HER2 drugs, immunotherapy, ramucirumab, or anti-claudin 18.2 drugs.

Your general health needs to be good enough to take part. This will be checked using a standard scale (WHO performance status 0-1), which means you are able to carry out most daily activities without much trouble. Your blood tests, including your blood count and how well your liver and kidneys are working, also need to be within a healthy range. If you are able to have children, both you and your partner would need to agree to use effective contraception during the study and for six months after your last dose of medication.

The research team will also need access to a sample of your tumour tissue, either from a surgery or a biopsy, to help them with the study. You also need to be willing to take part in additional biological studies, which will involve providing more samples. If you meet these main points, the study doctor will discuss all the detailed requirements with you to see if you are a good fit for this research.

If you join this study, you'll be assigned by chance (like flipping a coin) to one of two groups. One group will receive trifluridine/tipiracil plus fruquintinib, and the other group will receive trifluridine/tipiracil alone. Both medicines are given as tablets. You would have regular hospital visits, likely every few weeks, for check-ups, blood tests, and scans to see how the treatment is working. The study team will explain how and when to take your medicines. You will be closely monitored for any side effects. Treatment will continue for as long as it is helping you and you are tolerating it well. After you stop treatment, you will still have follow-up visits or calls to track your health and long-term effects. The total duration of your participation in the study will depend on how you respond to the treatment.